Chemotherapy negatively impacts the tumor immune microenvironment in NSCLC: an analysis of pre- and post-treatment biopsies in the multi-center SAKK19/09 study
Autor: | M L Amrein, S Savic-Prince, Adrian F. Ochsenbein, Michael A. Amrein, Elias D. Bührer, Rolf Jaggi, Sacha I. Rothschild, Lukas Bubendorf, Qiyu Li, Carsten Riether, O. Gautschi |
---|---|
Rok vydání: | 2020 |
Předmět: |
Male
Cancer Research Lung Neoplasms LAG3 Biopsy medicine.medical_treatment Immunology Gene Expression chemical and pharmacologic phenomena 610 Medicine & health 03 medical and health sciences 0302 clinical medicine Immune system Carcinoma Non-Small-Cell Lung Tumor Microenvironment Humans Chemotherapy Immunology and Allergy Medicine 030212 general & internal medicine Lung cancer TNFRSF18 business.industry FOXP3 Cancer medicine.disease Immune checkpoint Immune microenvironment Oncology 030220 oncology & carcinogenesis Cancer research Female Original Article business Non-small-cell lung cancer |
Zdroj: | Amrein, M. A.; Bührer, E. D.; Amrein, M. L.; Li, Q.; Rothschild, S.; Riether, C.; Jaggi, R.; Savic-Prince, S.; Bubendorf, L.; Gautschi, O.; Ochsenbein, A. (2021). Chemotherapy negatively impacts the tumor immune microenvironment in NSCLC: an analysis of pre-and post-treatment biopsies in the multi-center SAKK19/09 study. Cancer immunology, immunotherapy : CII, 70(2), pp. 405-415. Springer 10.1007/s00262-020-02688-4 Cancer Immunology, Immunotherapy |
ISSN: | 1432-0851 0340-7004 |
DOI: | 10.1007/s00262-020-02688-4 |
Popis: | Background Over the past few years, immune checkpoint inhibitors have changed the therapeutic landscape of non-small-cell lung cancer (NSCLC). Response to immune checkpoint inhibitors correlates with a pre-existing anti-tumoral immune response. Checkpoint inhibitors have been introduced as second-line therapy and are only very recently used as monotherapy or in combination with chemotherapy as first-line treatment of NSCLC. However, the effect of conventional first-line platinum-based chemotherapy on the immune infiltrate in the tumor is largely unknown. Methods We measured the gene expression of a custom set of 201 cancer- and immune-related genes in 100 NSCLC tumor biopsies collected before chemotherapy and 33 re-biopsies after platinum-based chemotherapy at the time point of progression. For 29 patients matched pre- and post-chemotherapy samples could be evaluated. Results We identified a cluster of 47 co-expressed immune genes, including PDCD1 (PD1) and CD274 (PD-L1), along with three other co-expression clusters. Chemotherapy decreased the average gene expression of the immune cluster while no effect was observed on the other three cluster. Within this immune cluster, CTLA4, LAG3, TNFRSF18, CD80 and FOXP3 were found to be significantly decreased in patient-matched samples after chemotherapy. Conclusion Our results suggest that conventional platinum-based chemotherapy negatively impacts the immune microenvironment at the time point of secondary progression. |
Databáze: | OpenAIRE |
Externí odkaz: |